Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating ...

On Tuesday, Johnson & Johnson (JNJ) stock saw a decline, ending the day at $152.64 which represents a decrease of $-2.40 or -1.55% from the prior close of $155.04. The stock opened at $154.53 and ...

Looking for the latest stock opportunities in December 2024? We have you covered. Click to read our top stock picks to ...

Johnson & Johnson has a high three-year median payout ratio of 71% (or a retention ratio of 29%), meaning that the company is ...

Get-Up 3 will feature Brittany Howard of Alabama Shakes, Mike Cooley of Drive-by Truckers, Lee Bains and more.

The first time Johnson & Johnson faced a lawsuit due to its talc-based baby powder causing cancer was way back in 1999. Since ...

HRSA’s threats of penalties led J&J to halt the plan, prompting a legal battle to protect its proposed changes. Johnson & ...

Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us ...

Historically an active player in the M&A space, Radnor-based Avantor has not found itself so busy in that realm during the ...

On Friday, Johnson & Johnson (JNJ) stock saw a decline, ending the day at $155.47 which represents a decrease of $-1.26 or -0.80% from the prior close of $156.73. The stock opened at $157 and touched ...

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

Julian Harrison gave his rating based on several factors surrounding Protagonist Therapeutics’ promising drug candidate, JNJ-2113. The upcoming Phase 3 trial data for JNJ-2113 in psoriasis is pivotal, ...